SAP Depleter Dose Assessment Study in Patients

Status Completed

Clinical Trial Summary

This study aims to provide safety information on the ligand, GSK2315698A. The pharmacokinetics and pharmacodynamics of the ligand will be determined together with the differences in routes of dose administration, namely the tolerability between intravenous versus subcutaneous dose administration. The study will be carried out in patients with systemic amyloidosis and the ability of GSK2315698A in depleting levels of serum amyloid protein (SAP) will be measured.

Clinical Trial Description

This study is an open label, dose characteristic study assessing safety and pharmacokinetic and pharmacodynamic considerations of GSK2315698A. GSK2315698A is a ligand known to bind to serum amyloid protein (SAP), a key component of an anti-SAP approach to the treatment of systemic amyloidosis. Safety assessments will include adverse events, vital signs, ECGs and other relevant clinical laboratory tests. Dose administration routes will also be determined focusing on the tolerability of intravenous dose administration versus subcutaneous. The study aims to recruit up to 30 patients with a medical diagnosis of systemic amyloidosis. Subjects will be asked to attend 2 dosing sessions, each session will involve an intravenous infusion of GSK2315698A over 48 hours followed by a single subcutaneous dose in session 1 and up to 3 subcutaneous doses in session 2 to be administered over a 24 hour period. ;

Study Design

Related Conditions & MeSH terms

Amyloidosis

Clinical Trial Details

NCT number	NCT01406314
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	October 13, 2011
Completion date	November 14, 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04893889` - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.	N/A
Withdrawn	`NCT04943302` - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis	Phase 2
Active, not recruiting	`NCT02909036` - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.	Phase 1
Completed	`NCT02816476` - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis	Phase 2
Completed	`NCT01083316` - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis	Phase 2
Completed	`NCT01527032` - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis	Phase 2
Completed	`NCT02545907` - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis	Phase 1/Phase 2
Recruiting	`NCT05263817` - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis	Early Phase 1
Active, not recruiting	`NCT03201965` - A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis	Phase 3
Withdrawn	`NCT02589860` - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02574676` - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Active, not recruiting	`NCT02260466` - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.	N/A
Withdrawn	`NCT02462213` - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging	N/A
Recruiting	`NCT05577819` - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF	N/A
Not yet recruiting	`NCT04985734` - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy	N/A
Active, not recruiting	`NCT03584022` - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial	N/A
Active, not recruiting	`NCT05235269` - A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis	Phase 2
Active, not recruiting	`NCT05199337` - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	Phase 1/Phase 2
Completed	`NCT02716103` - Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis